Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial. (linkinghub.elsevier.com)

Authors: Lyke KE … Miller RS Journal: Lancet Infectious Diseases Published: 2026-02-01 DOI: https://doi.org/10.1016/S1473-3099(25)00481-5